Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. Annual Report Summary (Fiscal Year Ended December 31, 2025)

Bluejay Diagnostics, Inc. operates at the intersection of high risk and high potential, a reality sharply reflected in its latest SEC 10-K filing for the fiscal year ended December 31, 2025. This summary distills the company's financial performance, operational developments, and key risks, offering investors a clear view of its current standing and future challenges.

Business Overview: Pioneering Sepsis Diagnostics

Bluejay Diagnostics, Inc. develops rapid, point-of-care testing solutions for critical care, primarily targeting sepsis and other inflammatory conditions. Its flagship product in development, the Symphony IL-6 test, measures the IL-6 biomarker in blood. This proprietary test, used with the "Symphony" analyzer, aims to deliver lab-quality results in about 20 minutes. This speed enables faster clinical decisions in Intensive Care Units (ICUs) and Emergency Rooms (ERs), which Bluejay believes could significantly improve patient outcomes where early intervention is crucial.

Financial Performance Highlights (Fiscal Year Ended December 31, 2025)

As an early-stage company, Bluejay Diagnostics remains pre-revenue, investing heavily in research and development.

• Revenue: The company reported $0.0 million in revenue for the fiscal year, as no products have yet received regulatory approval for commercial sale.
• Net Loss: Bluejay Diagnostics reported a net loss of $7.5 million for 2025, an increase from previous periods. This loss primarily stems from ongoing research and development (R&D) and operational costs.
• Operating Expenses: Operating expenses, largely driven by product development and administrative overhead, resulted in an operating loss of $6.8 million.
• Accumulated Deficit: The company's accumulated deficit—the total losses since inception—reached $41.5 million by year-end 2025. This figure highlights the substantial investment required to bring its technology to market.

Financial Health and Liquidity

As of December 31, 2025, Bluejay Diagnostics held approximately $6.5 million in cash and cash equivalents. At its current rate of spending, this cash will fund operations for less than 12 months. The company has historically funded operations by selling stock (equity financing) and expects to continue this practice. In 2025, Bluejay raised capital through equity offerings, selling common stock and warrants. This resulted in significant dilution, meaning existing shareholders now own a smaller percentage of the company. Importantly, Bluejay reported no significant long-term debt at year-end 2025, relying primarily on equity for funding.

Bluejay anticipates needing at least an additional $20 million by the end of fiscal year 2027 to sustain operations and achieve its development milestones. This need stems from its pre-revenue status and projected operational costs. The company's ability to continue operating depends heavily on its capacity to raise this additional capital. This funding is not guaranteed and may not be available on favorable terms, which could further increase shareholder dilution.

Management Discussion and Analysis (MD&A) Highlights

Bluejay's management highlighted both progress and significant challenges during 2025.

Key Developments and Achievements:

• Symphony Analyzer Development: Bluejay completed the pre-clinical development of the Symphony analyzer, its core diagnostic instrument.
• Clinical Trial Enrollment: The SYMON-II pivotal clinical trial achieved significant progress, enrolling approximately 583 of its 750 target patients. This trial is crucial for generating data needed for FDA submission.

Operational and Financial Hurdles:

• Manufacturing Delays: Persistent issues with the performance and reproducibility of test cartridge manufacturing present a primary challenge. Bluejay actively collaborates with its manufacturing partner, Sanyoseiko, to resolve these problems, which directly impact the ability to analyze clinical trial samples.
• Regulatory Timeline Shift: Due to manufacturing challenges, Bluejay now projects clinical trial sample analysis for the third quarter of 2026. Consequently, the company anticipates submitting its 510(k) application (a type of FDA clearance) for the IL-6 test in 2027, delaying potential FDA clearance.
• Significant Stock Price Decline: Since its IPO in November 2021, Bluejay's stock price experienced a dramatic decline of over 99.9%, resulting in substantial losses for early investors.
• Nasdaq Delisting Risk: The company faces a significant risk of delisting from the Nasdaq Capital Market. This risk arises because its stock price consistently trades below the $1.00 minimum bid price requirement. Additionally, Bluejay may be unable to meet a new Nasdaq rule requiring a minimum $5 million market value.

Future Outlook and Strategic Focus

Bluejay Diagnostics' immediate future focuses on overcoming manufacturing hurdles and advancing its lead product toward regulatory approval.

• Commercialization Pathway: Bluejay's primary strategic objective is to resolve manufacturing issues, complete clinical trial data analysis in late 2026, and submit the IL-6 test for FDA 510(k) clearance in 2027. This FDA clearance is essential for commercialization.
• Pipeline Expansion: Beyond the IL-6 test, the company plans to leverage the Symphony platform for additional critical care diagnostics. These include tests for cardiac conditions like heart attacks and congestive heart failure, contingent on the success of its initial product.
• Continued Fundraising: Given its pre-revenue status and projected operational needs, Bluejay anticipates needing substantial additional capital to sustain operations and achieve its development milestones. This will likely necessitate further equity financing, leading to additional shareholder dilution.

Competitive Position

The market for critical care diagnostics, especially for conditions like sepsis, is highly competitive and rapidly evolving. Bluejay aims to differentiate itself with its rapid, point-of-care Symphony IL-6 test, providing quick, lab-quality results for faster clinical decision-making.

Key competitive factors in this market include:

• Speed and Accuracy: Timely and reliable results are paramount in critical care settings.
• Ease of Use and Workflow Integration: Point-of-care devices must be user-friendly and integrate seamlessly into existing hospital workflows.
• Cost-Effectiveness: Pricing, relative to clinical utility and reimbursement rates, significantly influences adoption.
• Clinical Evidence and Regulatory Approvals: Robust clinical data and FDA clearance are essential for market entry and acceptance.
• Established Relationships: Incumbent diagnostic companies often have long-standing relationships with hospitals and healthcare providers.

Bluejay competes against established diagnostic companies offering centralized lab tests for sepsis biomarkers, as well as other companies developing rapid or point-of-care solutions. While the Symphony IL-6 test offers a unique combination of speed and point-of-care convenience for a specific biomarker, Bluejay faces challenges gaining market share against well-capitalized competitors with extensive sales and distribution networks. The successful commercialization and market adoption of its product depends on demonstrating clear clinical utility, securing favorable reimbursement, and overcoming the inherent advantages of larger, more established players.

Key Risks for Investors

Investing in Bluejay Diagnostics carries substantial risks, typical for early-stage medical device companies:

• Ability to Continue Operations (Going Concern Risk): The company has a history of significant losses and negative cash flows. Its ability to continue operating depends heavily on raising additional capital, which is not guaranteed and may not be available on favorable terms.
• Product Development and Regulatory Risk: The path to FDA approval is lengthy, costly, and uncertain. Unresolved manufacturing issues, unfavorable clinical trial results, or additional FDA requirements could cause further delays or prevent approval entirely.
• Market Acceptance and Reimbursement Risk: Even if approved, there is no guarantee that the Symphony IL-6 test will achieve broad market acceptance or secure adequate reimbursement from healthcare payers, both critical for commercial success.
• Stock Price Volatility and Delisting: The severe decline in stock price and the ongoing risk of delisting from Nasdaq could significantly impair liquidity and the ability to raise future capital.
• Reliance on Third Parties: Bluejay relies heavily on licensed technology from Toray and manufacturing services from Sanyoseiko. Disruptions in these relationships or performance failures by partners could severely impact the company's operations.
• Intellectual Property Risk: The company's success relies on protecting its intellectual property. Challenges to its patents or the inability to secure new patents could undermine its competitive position.
• Operational and Management Risks: With a lean management team, including the CEO also serving as the principal financial and accounting officer, there is a heightened risk regarding financial reporting oversight and overall operational management.

Bluejay Diagnostics, Inc. presents a high-risk investment opportunity with potentially transformative technology. Its future hinges on successfully resolving manufacturing challenges, securing regulatory approval, and effectively raising substantial additional capital in a challenging market environment.